Search results
AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
Investing.com· 7 days agoAbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
AbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up By Investing.com
Investing.com· 7 days agoAbbVie hikes 2024 earnings guidance as Q1 beat estimates, shares up
3 Dividend Stocks to Buy and Hold for the Next Decade
Motley Fool via Yahoo Finance· 6 days agoYou only have to find the right stocks worthy of holding for the long term and that pay attractive...
AbbVie raises annual profit forecast on strong Skyrizi sales
Reuters via Yahoo Finance· 7 days agoAbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates ...
AbbVie Reports First-Quarter 2024 Financial Results
WPRI Providence· 7 days agoReports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact ...
AbbVie lifts profit forecast after Skyrizi sales beat expectations
Reuters· 7 days ago, opens new tab raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the ...
Abbvie Inc (ABBV) Becoming More Attractive for Investors – Knox Daily
Knox Daily· 4 days agoAbbvie Inc’s recent filing unveils that its EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas unloaded Company’s shares for reported $3.72 million on Mar 20 ’24. In the deal ...
The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology via Yahoo Finance· 21 hours agoMerck & Co- $30.5bn Merck & Co’s revenues reached $60.1bn in FY 2023, with R&D investments peaking at $30.5bn. Displaying a staggering 126% growth...
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
Investopedia· 7 days agoShares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales...
CVS Caremark’s Policy Shift On Humira Biosimilars May Not Be What The Doctor Ordered
Forbes· 23 hours agoAs of March, the blockbuster autoimmune drug Humira (adalimumab) still held 96% of the market share...
